Grifols (GRF) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
The annual meeting is scheduled for April 17, 2025, to elect three directors and ratify the selection of the independent auditor for 2025.
Shareholders of record as of February 21, 2025, are entitled to vote, with one vote per share and no cumulative voting rights.
The Board recommends voting in favor of all director nominees and the auditor ratification.
Voting matters and shareholder proposals
Proposal 1: Election of three directors (Luke E. Sims, Donald G. Tyler, Neal F. Zalenko) for three-year terms.
Proposal 2: Ratification of Cohen & Company, Ltd as independent registered public accountants for 2025.
Shareholder proposals for the 2026 meeting must be received by November 14, 2025, for inclusion.
Board of directors and corporate governance
The Board is divided into three classes with staggered terms; nominees and continuing directors have diverse backgrounds in law, finance, and investment.
The Chairman and CEO roles are separated; the Chairman is not an Interested Person.
The Board held three meetings in 2024, with all directors attending at least 75% of meetings.
The Board has only one committee, the Audit Committee, and no standing nominating or compensation committees.
Seven directors are independent under NYSE rules; two are Interested Persons due to management and ownership roles.
Latest events from Grifols
- Three directors up for election and auditor ratification headline the 2026 annual meeting.GRF
Proxy Filing13 Mar 2026 - Revenue up 7%, profit more than doubled, and leverage improved to 4.2x in 2025.GRF
Q4 202526 Feb 2026 - Q2 revenue and EBITDA surged, leverage fell to 5.5x, and 2024 guidance was reaffirmed.GRF
Q2 20242 Feb 2026 - Q3 revenue up 12.4%, margins and cash flow improved, leverage down after SRAAS sale.GRF
Q3 202416 Jan 2026 - Record 2024 revenue, profit, and cash flow, with strong Biopharma growth and lower leverage.GRF
Q4 202419 Dec 2025 - Aims to double revenue to €14bn by 2034, led by Biopharma, innovation, and margin expansion.GRF
CMD 202510 Dec 2025 - Q1 2025 profit surged 179% on strong Biopharma and IG growth, with leverage down to 4.5x.GRF
Q1 202518 Nov 2025 - H1 2025 saw 7% revenue growth, higher EBITDA, net profit, and dividend reinstatement.GRF
Q2 202516 Nov 2025 - Q3 2025 saw strong profit growth, margin expansion, and improved leverage to 4.2x.GRF
Q3 202513 Nov 2025